







**24hrs
Treatment**

Fig. 1. Apoptotic dosage for T3 and other agents





Fig. 2. Apoptotic dosage for T3 and Kojic acid

A)



B) **24hrs Treatment**





Fig. 3. Suppression of Tyrosinase by T3 and other agents

A) 24hrs Treatment



B) 24hrs Treatment




Fig. 4. Suppression of Tyrosinase by T3 and other agents




Fig. 4. Suppression of Tyrosinase by T3 acetates




Fig. 5. Suppression of Tyrosinase by other agents




Fig. 6. T3's anti-tyrosinase effect persists beyond 24 hours






Fig. 7. T3's anti-tyrosinase activity leading to lower melanin content




Fig. 8. T3's anti-tyrosinase activity leading to lower melanin content




Fig. 9. Anti-pigmentation by T3 and other agents

B16 (Mouse melanoma, p3)
5 days treatment




Fig. 10. Anti-pigmentation by T3 and Arbutin




Fig. 11. Anti-pigmentation + tumor shrinkage by T3




Fig. 12. Anti-pigmentation + tumor shrinkage by T3






Fig. 13. Tumor Shrinkage caused by T3.

Start



After (1 month)




Human Trial

- ⇒ KOSE moisturizer with 2% palm tocotrienols
- ⇒ Applied topically day/night
- ⇒ No. Participants: 13
- ⇒ Period: 1 months
- ⇒ Photograph monthly

Fig. 14

A)



B)




Fig. 15. UV Protection by T3




Fig. 16. UV Protection by T3




Fig. 17. T3 Synergism with other agents




Fig. 18. T3 Synergism with other agents




Fig. 18E